Edition:
India

Divi's Laboratories Ltd (DIVI.NS)

DIVI.NS on National Stock Exchange of India

1,098.30INR
19 Jan 2018
Change (% chg)

Rs7.90 (+0.72%)
Prev Close
Rs1,090.40
Open
Rs1,090.00
Day's High
Rs1,103.60
Day's Low
Rs1,082.60
Volume
322,347
Avg. Vol
2,430,826
52-wk High
Rs1,142.00
52-wk Low
Rs532.65

Chart for

About

Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. The Company's geographical segments include India (Sales to customers within India) and other countries (Sales to customers outside India). Its products include Generic APIs, Intermediates, Peptide... (more)

Overall

Beta: -0.03
Market Cap(Mil.): Rs229,524.09
Shares Outstanding(Mil.): 265.47
Dividend: 10.00
Yield (%): 1.16

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Divi's Laboratories USFDA completed evaluation of co's corrective actions in response to warning letter

* Informed that USFDA completed evaluation of co's corrective actions in response to FDA's warning letter dated April 13 Source text for Eikon: Further company coverage:

10 Nov 2017

BUZZ-India's Divi's Labs surges; U.S. FDA to lift import alert on Visakhapatnam unit

** Shares of Divi's Laboratories Ltd surge as much as 21 pct to 1,117.6 rupees, highest since Dec 22, 2016

02 Nov 2017

BRIEF-India's Divi's Laboratories Sept-qtr profit falls

* Sept quarter net profit 2.07 billion rupees versus profit of 2.24 billion rupees year ago

31 Oct 2017

BUZZ-India's Divi's Labs falls; U.S. FDA observations more than procedural -report

** Divi's Laboratories Ltd falls as much as 9.4 pct to 870.1 rupees

27 Sep 2017

MEDIA-Import alert against Divi's Laboratories may be more than just 'procedural' - BloombergQuint

- Note: Reuters has not verified this story and does not vouch for its accuracy

27 Sep 2017

BRIEF-Divi's Laboratories gets form 483 with 6 observations at unit-2 on USFDA inspection

* Says Divi's Laboratories Limited, unit-2 has been inspected by US-FDA from September 11 to September 19, 2017

20 Sep 2017

Earnings vs. Estimates